Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$23.34 USD

23.34
2,836,056

-0.15 (-0.64%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $23.33 -0.01 (-0.04%) 4:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Cooper Companies (COO) Now

by Zacks Equity Research

Investors remain optimistic about Cooper Companies (COO) backed by strong CSI and CVI product portfolios and its continued leadership in the specialty lenses market.

Zacks Industry Outlook Highlights: McKesson Corp, West Pharmaceutical Services, Cardinal Health, Align Technology and Dentsply Sirona

by Zacks Equity Research

Zacks Industry Outlook Highlights: McKesson Corp, West Pharmaceutical Services, Cardinal Health, Align Technology and Dentsply Sirona

Trina Mukherjee headshot

3 Stocks to Capitalize on Promising Dental Supplies Industry

by Trina Mukherjee

Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.

DENTSPLY SIRONA (XRAY) at a 52-Week High: What's Driving It?

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) is optimistic about growth in CAD/CAM business arm along with its recent product launch and strategic buyouts.

DENTSPLY SIRONA (XRAY) Q4 Earnings & Revenues Beat Estimates

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) witnesses consumable revenue growth in the fourth quarter.

Why Earnings Season Could Be Great for DENTSPLY (XRAY)

by Zacks Equity Research

DENTSPLY (XRAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Thermo Fisher (TMO) Rides on Pharma & Biotech Amid Pandemic

by Zacks Equity Research

Customers in Thermo Fisher's (TMO) industrial and applied end markets get affected by business disruptions due to the pandemic.

What's in Store for Fulgent Genetics (FLGT) in Q4 Earnings?

by Zacks Equity Research

We expect strong demand for Fulgent Genetics' (FLGT) end-to-end tests for COVID-19 to have continued through the fourth quarter.

Integra (IART) Arms Grow Sequentially Despite Supply Issues

by Zacks Equity Research

Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically.

DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect weak segmental performance.

Bruker (BRKR) Rides on Product Launches Amid COVID-19 Woes

by Zacks Equity Research

Within Bruker's (BRKR) Nano Group Semiconductor metrology revenues have been steady with order rates improving as semi metrology equipment markets are witnessing a rebound.

Dentsply International (XRAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Urmimala Biswas headshot

4 Medical Products Stocks Set to Beat This Earnings Season

by Urmimala Biswas

Rebound in sales volumes and rise in COVID-19 support products sales make us optimistic about MDT, MASI, XRAY and COO's results.

LabCorp's (LH) New Antigen Test to Spot Active COVID-19 Virus

by Zacks Equity Research

LabCorp's (LH) new antigen test is the newest development to detect COVID-19 infection at every single stage, from diagnostic testing to vaccination trails.

Medtronic (MDT) Progresses in SNM With Updated InterStim Label

by Zacks Equity Research

Medtronic (MDT) expects this updated labeling with wider procedural options and shorter wait time to improve patient access to MRI exams and add more flexibility for MRI providers.

Owens & Minor (OMI) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

We expect the strength in demand for Owens & Minor's (OMI) PPEs to have continued through the fourth quarter.

Ecolab's (ECL) Certified Program to Build Customer Confidence

by Zacks Equity Research

Ecolab's (ECL) science-backed comprehensive program to help food retailers to support customer confidence.

Lower Bulk Purchases May Weigh on Medtronic (MDT) Q3 Earnings

by Zacks Equity Research

Medtronic's (MDT) diabetes care, robotics surgery and neuromodulation lines are expected to have performed well in Q3.

Here's Why You Should Hold on to McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from the multi-year strategic growth initiative and strength in the Distribution Solutions segment.

Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) fourth-quarter results are likely to reflect gains from the Global Healthcare and Life Sciences segment.

OPKO Health (OPK) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

OPKO Health's (OPK) fourth-quarter results are likely to reflect solid performance from Services and Products segment and RAYALDEE.

Invitae (NVTA) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Invitae's (NVTA) fourth-quarter results are likely to reflect strength in genetic testing.

Henry Schein (HSIC) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Henry Schein's (HSIC) medical business' PPE sales are likely to have maintained its momentum along with global recovery trends of the dental business during Q4.

Exact Sciences (EXAS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Precision Oncology business is likely to have continued to aid Exact Sciences' (EXAS) performance in the fourth quarter of 2020 amid the coronavirus-led economic doldrums.

What's in Store for Pacific Biosciences' (PACB) Q4 Earnings?

by Zacks Equity Research

Pacific Biosciences' (PACB) fourth-quarter results are likely to reflect strength in its Sequel system.